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ABSTRACT
IDENTIFICATION OF NOVEL PHOSPHORYLATION SITES IN SARS-CoV-2
NUCLEOCAPSID PROTEIN
Josie Daldegan Rezende

COVID-19, the 2019 disease outbreak, continues to cause severe mortality
worldwide. Fast and reliable tests that identify the SARS-CoV-2 virus, which is
responsible for causing the COVID-19 disease, are crucial for controlling the spread of
the virus. Antigen tests are ideal for the rapid diagnosis of COVID-19. Current antigen
tests for COVID-19 detect the SARS-CoV-2 nucleocapsid (N) protein. The nucleocapsid
is the most abundant protein produced by the virus upon infection, which makes it a
superior target for detection by an antigen test. Nucleocapsid proteins from several
coronaviruses, including SARS, have previously been shown to be modified by
posttranslational modification (PTM), including phosphorylation. PTMs are important
mechanisms to increase the functional diversity of the virus within its host cell and
modulate the antiviral response. Antigen tests require an antibody to bind to nucleocapsid
protein, however, phosphorylation may differ between the nucleocapsid used to elicit the
diagnostic antibody and phosphorylation on the viral protein in an infected person. In this
research, his-tagged SARS-CoV-2 nucleocapsid protein was expressed in insect cells
using a baculovirus expression system and analysis of purified samples using bottom-up
proteomics approach followed by ESI-MS/MS along with MALDI-TOF analysis was
used to localize phosphorylation sites in the SARS-CoV-2 nucleocapsid protein, which

may benefit the development of better antigen tests. Results from MALDI shows that N
protein is phosphorylated by an average of 13 phosphate groups. A total of 12
phosphopeptides were identified by ESI-MS/MS, of which 3 are novel sites not
previously reported (T135, T265 and T329).
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CHAPTER 1: INTRODUCTION
1.1 COVID-19 disease
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus
causes Coronavirus disease 2019 (COVID-19). It was first reported in China by the
World Health Organization (WHO) [1]. SARS-CoV-2 is highly infectious, causing severe
mortality worldwide and rapidly developing into a pandemic. By January 1st, 2022,
SARS-CoV-2 had infected over 36 million people worldwide and killed more than
691,000 individuals [2]. Although effective vaccines against SARS-CoV-2 have recently
been developed, a better understanding of the epidemiology and the viral pathogenesis of
SARS-CoV-2 infections in humans is still urgently needed as a basis for the development
of effective products for diagnosing, treating, preventing, and controlling the spread of
COVID-19 infectious disease [3].
1.2 COVID-19 Testing
The data provided from testing the population and the number of tests that are
been performed provides us with a perspective into the pandemic and how the virus is
spreading. Without testing the true number of infections may be far higher than the
number of confirmed cases, according to source from February 2022 [2]. Fast, sensitive,
and accurate early diagnostic testing allows us to identify infected individuals and
provide a quick response for prevention and treatment of the disease. To this extent, the
spread of the virus can be better controlled, and the acute phase of the pandemic could
end [3]. Early availability of diagnostic testing plays an important role in patient
management and public health [3].
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There are currently three main types of tests to detect the SARS-CoV-2 virus. The
molecular test reverse transcription-polymerase chain reaction (RT-PCR) test is
extremely specific, and it is the most accurate test, with the lowest limit of detection. In
order to test the genetic information of the virus in the laboratory, a respiratory or saliva
sample from the person being tested would be taken and analyzed for potential infection
of SARS-CoV 2 [4]. However, this test has some limitations. First, the results can take a
few hours to more than a week to be ready depending on the location and resources,
which is a drawback for early diagnostic testing. Second, it has a high cost due to the
complexity of the technique requiring highly trained professionals and high-cost
equipment. Also, false-negative amplification results might occur from cross-react with
the non-specific nucleic acid. An alternative diagnostic approach, the antibody test, also
known as the serology test, is a fast diagnosis test. It detects antibodies that the immune
system develops in response to the viral infection, but it does not necessarily detect the
presence of the virus itself. Our bodies can take several weeks to develop antibodies
against the virus, and it can remain in the body for an undetermined amount of time. So,
although the antibody test is a quick test, it does not diagnose an active infection.
The antigen test, by contrast, detects a specific viral antigen providing an
indication of active coronavirus infection. In general, the test is cheaper and much faster
than the molecular RT-PCR test. The accessibility of the various home antigen tests
makes it easier for individuals to test themselves more often and without presenting to
medical care or a testing center [2]. The COVID-19 antigen test is therefore ideal for
early diagnostic testing of SARS-CoV-2.
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1.3 Antigen Test
Currently, most COVID-19 rapid antigen tests on the market target SARS-CoV-2
nucleocapsid (N) protein. SARS-CoV-2 N protein is the most abundant viral protein
produced within the infected cells [5]. The presence of IgA, IgM, and IgG antibodies
against nucleocapsid antigen have been confirmed by immunoblot assay on patients
infected with COVID-19 [6]. Research results show that SARS-CoV-2 nucleocapsid
protein has a high specific antigen detection of 100%, and a sensitivity of 75% compared
to the nucleic acid test, in the early phase of infection [7]. Although the antigen test is
highly specific, it is usually less sensitive than RT-PCR test, which can lead to potential
false negative results or less accurate results overall [8][9]. Because of its abundance and
antigenicity, the SARS-CoV-2 nucleocapsid protein is an ideal target for early antigen
diagnostic detection for COVID-19 infection. However, improvements need to be made
to increase antigen test sensitivity for better accuracy of results. Epitope binding of
antibodies and therefore, antigen test sensitivity may be influenced by posttranslational
modification (PTM) of the antigen. Identification, quantification, and characterization of
PTMs on SARS-CoV-2 nucleocapsid protein can help to understand antigen binding,
molecular recognition, and the development of new types of antibodies that are more
specific, have higher affinities and are not affected by differences in posttranslational
modifications between the viral antigen and the recombinant antigen typically used to
elicit diagnostic antibodies for the antigen test.
1.4 SARS-CoV-2 Virology
SARS-CoV-2, which has a long RNA genome size of about 29.9 kb [10], belongs
to the betacoronavirus genus, one of the four genera of coronavirus. The virus consists of
an enveloped, single-stranded positive-sense RNA coated with nucleocapsid protein and
3

is packed with three structural proteins including membrane (M) protein, envelope (E)
protein and spike (S) protein. The genome also encodes 16 non-structural proteins (nsp116), which contribute to survival, signaling, and replication of the virus as well as 7
accessory proteins responsible for attenuating host response against SARS-CoV-2
[10][11].
The spike protein is responsible for fusion with the host cell membrane, allowing
the virus to penetrate the host cell causing infection. Coronavirus nucleocapsid protein, as
previously reported from other viruses, plays a key role in viral replication, transcription,
and translation [5][12]. N protein is essential for the SARS-CoV-2 life cycle and plays
critical roles in viral RNA synthesis as a multifunctional protein [13]. Spike and
nucleocapsid protein antigens from SARS-CoV-2 are highly immunogenic [14][15], and
they are the target for diagnosis and treatment of COVID-19. However, the spike protein
is more prone to mutations [16] that affect antibody binding, with several cases already
reported [17][18], which is a drawback for the development of diagnosis and treatment of
COVID-19.
The SARS-CoV-2 N protein is 419 amino acids in length and predicted to be 46
KDa in mass, and it binds to the viral RNA genome via its N-terminal domain [6]. The N
protein contains two domains, an N-terminal RNA binding domain (NTD), and a Cterminal oligomerization domain (CTD), which are connected by linker containing a
serine-arginine rich region (SR‐rich; 176–204 aa), Figure 1B [13]. Furthermore, there is
also an interaction between N protein and coronavirus M (membrane) protein mediated
by the serine-arginine rich domain [19].
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Figure 1: Coronavirus structure and SARS-CoV-2 Nucleocapsid protein. (A) Structure of human SARSCoV-2 coronavirus virion. (Reprinted from “Human Coronavirus Structure”, by BioRender.com (2022).
Retrieved from https://app.biorender.com/biorender-templates). (B) Schematic diagram of SARS-CoV-2
genome structure and domain structure of the 419 amino acid N protein (not to scale) with NTD domain in
purple which represent the RNA-binding region, the SR-rich motif in yellow, and the CTD domain in
orange which represents the oligomerization region. (Adapted from “Genome Organization of SARSCoV”, by BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates).

1.5 Posttranslational modification
Posttranslational modifications (PTM) of proteins involve the covalent addition of
functional groups, usually via enzymatic catalysis. Phosphorylation, which is the addition
of a phosphate group, usually to a serine, threonine, or tyrosine residue, is an essential
posttranslational modification. Antigenicity of the recombinant nucleocapsid protein has
been

shown

to

be

closely

linked

to

nucleocapsid

phosphorylation

[20].

Dephosphorylation of coronavirus nucleocapsid protein increases its binding affinity to
viral RNA over cellular RNA. Phosphorylation of coronavirus nucleocapsid protein,
5

regulated by kinases, is required to release RNA for viral infection [21]. Phosphorylation
and dephosphorylation of coronavirus nucleocapsid protein control the viral life cycle in
the host cell [22]. SARS-CoV-2 infection promotes activation and production of a kinase
that arrests the cell cycle and rewires the phosphorylation status of both host and viral
proteins [23].
The coronavirus N protein is mainly modified by phosphorylation, but
modifications by arginine methylation [24], proteolytic cleavage, and ADP-ribosylation
[25] were previously detected as well. Nucleocapsid protein from other viruses are often
also phosphorylated. Phosphorylation of coronavirus N protein was identified previously
in the Mouse hepatitis virus (MHV) [22][26], the Transmissible gastroenteritis virus
(TGEV) [27], the Infectious bronchitis virus (IBV) [21], and the severe acute respiratory
syndrome coronavirus (SARS-CoV) [28][29].
This research aims to map phosphorylation sites of SARS-CoV-2 Nucleocapsid
protein, using tagged recombinant protein expressed in insect cells. The previous
literature along with computational predictions suggest that N protein is highly
phosphorylated. This study utilizes mass spectrometric analysis of intact N protein and
peptides using matrix-assisted laser desorption/ionization (MALDI-MS). Additionally, a
bottom-up proteomic approach was used to identify phosphorylated sites using
electrospray ionization mass spectrometry (ESI-MS).

MALDI-MS results show an

average of 13 phosphorylated sites in recombinant SARS-CoV-2 N protein and ESI-MS
results confirmed 12 phosphorylated serines and threonines including 3 novel
phosphorylated sites.
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CHAPTER 2: EXPERIMENTAL METHODS
2.1 Recombinant N protein purification using IMAC column
Recombinant SARS-CoV-2 Nucleocapsid protein expressed in baculovirus using
Bac-to-Bac™ Baculovirus Expression System (Thermo Fisher) was purified from insect
cells. The Nucleocapsid protein was cloned into two versions, one version with a 7x
histidine-tag and green fluorescent protein (GFP) tag on the C-terminus and the second
version with only a 7x histidine-tag on the C-terminus. The recombinant Nucleocapsid
protein was then affinity purified using Co-NTA (cobalt-nitrilotriacetic acid) resin as
follows; the 10ml cell lysate was harvested by centrifugation at 12,000 rpm for 25 min at
4°C after thawing from −80℃ on ice and adding 100 µl of protease inhibitor solution (18
mg/ml phenylmethylsulphonyl fluoride 0.3 mg/ml pepstatin A in ethanol). 100 µl of 1 M
HEPES 7.4 was added in order to raise the pH to about 7. The supernatant was loaded
onto a 750 µl HisPur™ Cobalt Resin column, equilibrated with 5000ul equilibration
buffer (20 mM HEPES [pH 7.4], 150 mM NaCl). After being incubated for 45 min with
tilting on ice, extract was allowed to flow through, and the column with resin was washed
two times with 10 ml of 20 mM HEPES pH 7.4, 1.25 M NaCl buffer, and two times with
10 ml of buffer 20 mM HEPES 7.4, 150 mM NaCl, 10 mM imidazole buffer. Purified N
protein was sequentially eluted from the column two or three times with 1 ml of 20 mM
HEPES 7.4, 150 mM NaCl, 250 mM imidazole buffer. The samples were collected, and
fractions were analyzed by SDS-PAGE. A buffer exchange step (Nanosep® Centrifugal
Devices with Omega™ Membrane 10K) was used to desalt and to increase the
concentration of the N protein fractions.
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2.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
Buffer-exchanged affinity chromatography purified N protein preparations were
separated by SDS-PAGE. 4x gel loading buffer was added to samples to a final
concentration of 1x. Samples were then heated to 70°C for 5 min and 1/20 volume of 0.5
M iodoacetamide was added and samples were incubated at room temperature for 10 min
in the dark. The purpose of this procedure was to denature the N protein. Samples were
loaded onto precast polyacrylamide gels (Invitrogen NuPAGE™ 4 to 12%, Bis-Tris, 1.0
mm, Mini Protein Gel, 15-well) and electrophoresis was performed using 1x MOPS
running buffer and 500 µl Invitrogen NuPAGE™ Antioxidant at 190 volts for 45 min.
Precision Plus Protein Standards™ Dual Color (BioRad) were used as a marker. Gels
were stained using colloidal Coomassie dye G-250 (GelCode™ Blue Stain Reagent,
Thermo Fisher) on a rocking platform overnight and distained in water. N protein band
was compared to BSA standards to estimate the protein concentration on the gel using a
public domain Java image processing program, Image J [30].
2.3 In-gel digestion and peptide purification
The N protein bands were cut out and diced into small pieces, with each tube
receiving ∼3 µg of N protein. Gel pieces were de-stained until clear using 50 mM
ammonium bicarbonate (ABC) and 50% acetonitrile (ACN) and dehydrated with 100%
ACN. Aspiration was used to remove ACN, and gel pieces were air dried. Dried gel
pieces were rehydrated with 10 µl of the indicated concentration of Lys-C enzyme or a
combination of Lys-C and trypsin according to Table 1. After 10 min on ice, 50 µl of
Lys-C buffer (25 mM Tris-HCl, pH 8.0, 1 mM EDTA) was added and incubated at 37°C
according to time indicated in Table 1. After removal of supernatant, additional
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extraction was performed by shaking the gel pieces with 175 µl of peptide extraction
buffer (1.67% FA, 67% ACN, 0.05% TFA), followed by 100 µl of 0.1% FA. Then,
extracted peptides were purified over reverse-phase C18 column packed into a
microcapillary tube, washed three times with 50 µl of 0.1% TFA, 90% ACN with 0.1%
TFA and 0.1% acetic acid respectively [31]. Samples were sequentially eluted with 50 µl
40% ACN, 0.1% acetic acid and then with 90% ACN, 0.1% acetic acid.

Procedure

Enzyme concentration

1

Trp 0.05 µg/µl
LysC 0.05 µg/µl
LysC 0.05 µg/µl + Trp 0.00005 µg/µl
LysC 0.05 µg/µl + Trp 0.00005 µg/µl
LysC 0.05 µg/µl
LysC 0.05 µg/µl + Trp 0.00005 µg/µl
LysC 0.05 µg/µl + Trp 0.0005 µg/µl
LysC 0.05 µg/µl + Trp 0.005 uµg/µl

2

3

Enzyme incubation incubation
amount
time
temperature
10 µl
3 hours
10 µl

3 hours
5 hours

10 µl

37°C

3 hours

Table 1: Enzyme concentration and amount used in different protein digestion procedures.

2.4 ESI Mass spectrometry
Samples were analyzed with a nano-LC 1200 (Thermo Fisher) using a
EASYspray PepMap RSLC C18 3 micron, 100 Å, 75 µm by 15 cm column using a
Orbitrap Lumos instrument (Thermo Fisher) and separated using a 120 minute gradient.
For HCD fragmentation experiments, the instrument was operated in datadependent mode, and the most abundant ions were selected in each full scan for the
maximum parallelizable time and sequentially fragmented by high-energy collisional
dissociation using a normalized collision energy of 28%; dynamic exclusion was enabled.
Target resolution was 120,000 for MS. The quadrupole isolation window was 1.4 m/z,
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and the MS/MS used a maximum injection time of 250 ms with 1 microscan and a
minimum intensity threshold of 5E3. Charge states were limited to between 2-6.
For ETD experiments, the instrument was also operated in data-dependent mode,
and the most abundant ions were selected in each full scan for the maximum
parallelizable time and sequentially fragmented by electron transfer dissociation with a
reaction time of 50 ms, a reagent target of 1E6, and a maximum reagent injection time of
200 ms; dynamic exclusion was enabled. Target resolution was 120,000 for MS. The
quadrupole isolation window was 1.4 m/z, and the MS/MS used a maximum injection
time of 250 ms with 1 microscan and a minimum intensity threshold of 5E3. Charge
states were limited to between 4-8.
2.5 Raw data processing
MaxQuant (v 2.0.3.0) was used to process all ESI-MS raw data, with the
recombinant N protein sequence and a Trichoplusia ni (T. ni) protein sequence database
from the insect host cells. MaxQuant default parameters were used with the exception
that label-free quantification was turned on. Numbers of modifications allowed per
peptide was set to 8.
2.6 In-solution phosphatase treatment and Lys-C digestion
Purified recombinant SARS-CoV-2 N protein was dephosphorylated using CIAP
(Calf Intestinal Alkaline Phosphatase) (Invitrogen™) and recommended manufacture’s
protocol was performed with 1 hour and 30 min incubation at 37°C. Purified recombinant
SARS-CoV-2 N protein was also dephosphorylated using lambda protein phosphatase
(400,000 U/ml, New England Bio Labs Inc.) with 1 hour and 30min incubation at 30°C
following manufacture’s protocol. Protein digestion with Lys-C was performed on
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sample treated with lambda protein phosphatase and buffer exchanged into Lys-C
digestion buffer. 10ul of 0.1µg/µl Lys-C was added to 30ul (~ 2 µg) of Nc protein
concentrated from buffer exchange.
2.7 Ultra-thin layer
For the analysis and comparison of N protein and peptides, MALDI-TOF/TOFMS (Bruker Ultraflextreme) was used. The preparation for the matrix-assisted laser
desorption was done following the ultra-thin layer method [32]. Intact and
dephosphorylated protein and peptides had matrix crystals incorporated into them
prepared with α-Cyano-4-hydroxycinnamic acid (4-HCCA). The thin layer substrate
solution (1 part of saturated 4-HCCA and 3 parts of isopropanol) was added to a cleaned
MALDI plate. The matrix solution was prepared with 1:3:2 FWI (formic acid, water, and
isopropanol) and saturated 4-HCCA. The analyte solutions were diluted in matrix
solution to a final concentration of ~ 2.5 µM. 1µl of each sample/matrix solution was
spotted on the plate to crystallize of matrix and analyte and the excess liquid was
aspirated with a vacuum line. 0.5µl of myoglobin/matrix mixture was used as a calibrant
and applied in a similar manner with a final concentration of 0.1µM. The spots were
washed twice with 2 µl of ice cold 0.1% TFA solution aspirating the excess liquid with a
vacuum line.
2.8 MALDI Mass spectrometry
Samples spotted on an MTP 384 well polished steel target plate were analyzed
using the Ultraflextreme MALDI-TOF/TOF mass spectrometer (Bruker Daltonics,
Billerica, MA, USA) equipped with a smart beam-II laser set at 1,000 Hz repetition rate.
The MS spectra were externally calibrated with Protein Calibration Standard I. The Lys11

C digested Nc peptides were analyzed from 5,000-10,000 m/z range while the intact Nc
proteins were analyzed from 40,000-60,000 m/z range in the linear positive mode with
matrix suppression set at 4,500 and 55,000 Da respectively. A total of 3,000 accumulated
shots were acquired for each sample. The following ion source parameters were used: ion
source 1 at 25.00 kV; ion source 2: 23.30 kV; lens at 6.56 kV and pulsed ion extraction at
400 ns. MALDI-TOF spectra were acquired using the FlexControl 3.4 acquisition
software while the raw data were processed using the FlexAnalysis 4.0 software.
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CHAPTER 3: RESULTS AND DISCUSSION
3.1 SARS-CoV-2 SR-rich domain is predicted to be highly phosphorylated
A protein multiple sequence alignment performed on N protein from SARS-CoV2, SARS-CoV, MHV, TGEV, and IBV using UniProt [33] is shown in Figure 2.
Previously determined serine and threonine phosphorylation sites are highlighted in
green. All the nucleocapsid proteins are phosphorylated in the serine-arginine rich
domain, highlighted in yellow, as shown in previous studies [21][22][26][27][28][29].
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Figure 2: Protein Multiple Sequence Alignment using Clustal Omega [34]. NCAP_SARS2: SARS-CoV-2
Nucleocapsid protein. NCAP_SARS: SARS-CoV Nucleocapsid protein [28][29]. NCAP_CVMJH: MHV-
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JHM Nucleocapsid protein [26]. NCAP_CVMA5: MHV-A59 Nucleocapsid protein [22]. NCAP_IBVB: IBV
Nucleocapsid protein [21]. NCAP_CVPPU: TGEV Nucleocapsid protein [27]. Identical and similar
residues are boxed in blue lines. Previously experimentally identified phosphorylated amino acids are
highlighted in green background. S176 residue (highlighted in red) was computationally predicted to be
phosphorylated in UniProt [33] by homology to SARS. The serine-arginine rich domains are highlighted in
yellow background.

Molecular evolutionary research has shown that SARS-CoV-2 belongs to the beta
coronavirus B lineage, in the same branch as SARS-CoV. As they belong to the same
protein family, nucleocapsid protein from SARS-CoV and SARS-CoV-2 share 79%
sequence identity [35] and 90% homology [10][36]. A posttranslationally modified
residue on SARS-CoV nucleocapsid protein on serine position 176 (P0DTC9 ·
NCAP_SARS2) was previously reported in UniProt [33].
Bioinformatic approaches can be an important tool to predict phosphorylation of
proteins. Computational analysis was therefore used to identify possible phosphorylation
sites on N protein. A phosphorylation prediction program, NetPhos 3.1, analysis shows
22 possible serine phosphorylation sites and 11 possible threonine phosphorylation sites
shown in Figure 3 [37][38]. Figure 3 shows a dense region of possible serine
phosphorylation between amino acids 141 and 197, which is within the serine-arginine
rich domain. In conclusion, the SR-rich domain is predicted to be highly phosphorylated,
and some other sites outside the SR-rich domain are also predicted to be phosphorylated.
A comparison of previous experimental data from UniProt [33] with
computational predictions from NetPhos 3.1 [38], both shows phosphorylation on serine
176. While NetPhos 3.1 [38] is based on computational analysis and predicted results,
UniProt [33] results are based on actual data. The data from UniProt [33] and the
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predictions from NetPhos 3.1 [38] provide positive indications for discovering SARSCoV-2 nucleocapsid protein phosphorylation sites.

Figure 3: NetPhos 3.1 phosphorylation site prediction. Predicted phosphorylation sites of SARS-CoV-2
Nucleocapsid protein on serine (in purple) and threonine (in green) amino acids. (A top) The SR-rich
region is boxed in blue lines within the amino acid sequence. (A bottom) NetPhos 3.1 threshold score is
0.7. (B) Location of predicted phosphorylation sites of SARS-CoV-2 N protein with their corresponding
NetPhos 3.1 scores are presented in a table [38].

3.2 Overall phosphorylation state of recombinant SARS-CoV-2 N protein via
MALDI-MS
Accurate molecular mass measurements via MALDI-TOF-MS can indicate the
presence and identity of posttranslational modifications of proteins and peptides. The m/z
values generated from MALDI-TOF/TOF-MS usually represent the true molecular mass
as most of the ions have +1 charge. Intact recombinant SARS-CoV-2 N protein was
compared before and after treatment with lambda phosphatase (Figure 4BC) and CIP
phosphatase (Figure 4DE). Intact protein represents the full length N protein not
proteolytically digested into peptides. Our his-tagged recombinant SARS-CoV-2 N
protein has a predicted molecular weight of 47,467 Da [39], including the his-tag, which
16

matches well with our MALDI data of 47,578 Da from Figure 4E, and 47,354 Da from
Figure 4B representing the dephosphorylated intact recombinant SARS-CoV-2 N protein.
Comparing the MALDI peaks between the samples that were treated with protein
phosphatase and samples that were not treated with protein phosphatase (Figure 4) we
can observe that the control samples, which were not treated with protein phosphatase,
have a higher m/z than the samples treated with protein phosphatase. The mass difference
between the samples can be related to the phosphorylation of N protein.
The m/z mass difference between the phosphorylated (Figure 4B) and
dephosphorylated (Figure 4C) intact recombinant SARS-CoV-2 N protein using lambda
phosphatase is 764 Da and the m/z mass difference between the phosphorylated (Figure
4D) and dephosphorylated (Figure 4E) intact recombinant SARS-CoV-2 N protein using
calf intestinal phosphatase (CIP, Invitrogen) is 1040 Da. Assuming that the only
difference between those two groups of samples is that in Figure 4BD the samples were
not treated with protein phosphatase and in Figure 4CE the samples were treated with
protein phosphatase in order to remove the phosphoryl groups, then we can conclude that
the mass difference implies that the recombinant SARS-CoV-2 N protein is indeed
phosphorylated. The loss of a phosphoryl group from the reaction of a phosphorylated
serine and/or threonine with a protein phosphatase represent a shift in molecular mass of
minus 80 Da [40][41]. The m/z discrepancy of 1040 Da thus reveals that the recombinant
SARS-CoV-2 N protein treated with CIP phosphatase were modified by thirteen
phosphoryl groups. The m/z discrepancy of 764 Da reveals that the recombinant SARSCoV-2 N protein treated with lambda phosphatase were modified by at least nine
phosphoryl groups.
17

Some considerations on those peaks should be taken into account. First, Figure 4E
shows smooth peaks while the others MALDI shows peaks more jagged and uneven due
to the difference in scale intensity (figure 4E has maximum intensity of 2.5x 10^4 and the
other have maximum intensity of ~1.25 x 10^3). Furthermore, it is notable that Figure 4C
shows a long shoulder on the right and on the left of the peak. Shoulder peaks are
frequently observed as a result of the existence of two closely unresolved compounds.
However, the possibility that this shoulder might represent heavier and lighter versions of
the same compound cannot be disregarded. If this is the case, the shoulder peak will
indicate versions of SARS-CoV-2 N protein with higher phosphorylation states as well
with lower phosphorylation state. Even without considering the shoulder, this peak is
broader than the peak in Figure 4E which also might represent different phosphorylated
versions of SARS-CoV-2 N protein. Taken together, this evidence suggests that the
lambda phosphatase-treated sample (Figure 4C) may not have been completely
dephosphorylated. Another corroboration that supports this idea is the fact that the
MALDI peak from the sample treated with lambda has a lower intensity compared to the
sample treated with CIP. Phosphorylation suppresses the peak intensity in MALDI, and
ESI [42] and the signal is further diluted by the presence of multiple phosphorylation
sites.
Additionally, confirmation of efficacy of the dephosphorylation reaction using
lambda can be interpreted from SDS-PAGE (Figure 4A) as the band from a sample
treated with lambda phosphatase is lower than the band from a control sample not treated
with lambda. The lower band represent samples with lower molecular weight due to the
removal of phosphate groups from the sample treated with lambda phosphatase.
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However, there is no proof that the reaction with lambda went to completion by removing
all phosphate group from the N protein, based on SDS-PAGE results. The SDS-PAGE
bands were observed to be slightly slanted perhaps due to the presence of high salt
concentration in the phosphatase buffer.

Figure 4: MALDI results of intact nucleocapsid protein. (A) SDS-PAGE of recombinant SARS-CoV-2 N
protein treated and untreated (control) with lambda protein phosphatase. (B) Intact recombinant SARSCoV-2 N protein MALDI analysis before lambda phosphatase treatment. (C) Intact recombinant SARSCoV-2 N protein MALDI analysis after lambda phosphatase treatment. (D) Intact recombinant SARS-CoV2 N protein MALDI analysis before CIP phosphatase treatment. (E) Intact recombinant SARS-CoV-2 N
protein MALDI analysis after CIP phosphatase treatment.
Expasy results from in silico digestion of our his-tagged recombinant
SAR-CoV-2 N protein with the
protease
Lys-C
predicts
the
peptide
GFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESK containing 64 amino
acids, which includes the SR-rich domain, to have a peptide mass of 6544.07 Da (

Figure 6A),

without posttranslational modifications. The Figure 5B represents the

MALDI spectra of peptides of recombinant SAR-CoV-2 N protein from digestion with
Lys-C and the partial lambda phosphatase treatment. This means that this sample will
have peptides that are phosphorylated and peptides that are dephosphorylated as well.
The dephosphorylated spectrum shows a peak with m/z of 6544.2 Da, which we can
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conclude represents the SR-domain containing peptide, due its high accuracy match with
the predicted mass from Expasy.
However, considerations about the peptide’s formation from lambda protein
digestion with Lys-C must also be addressed. The peak with m/z 7695.1 Da is shown in
the sample treated with lambda phosphatase (Figure 5B), but the same peak is not shown
in the intact sample, which was not treated with lambda protein phosphatase (Figure 5A).
Additionally, this 7695.1 Da peak matches with one of the predicted peptide masses from
lambda protein digestion with Lys-C equal to 7694.657 Da, highlighted in yellow on
Figure 6B. This led us to conclude that the peak is associated with a peptide from the
lambda phosphatase digested with Lys-C. Phosphorylated peptide can not be observed in
MALDI analysis of the Lys-C digested protein and this might be due the signal
suppression from phosphorylation [42].
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Figure 5: MALDI spectra of peptides from recombinant SARS-CoV-2 N protein digested with Lys-C. (A)
N protein not treated with lambda phosphatase. (B) N protein partially treated with lambda phosphatase.
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Figure 6: Expasy peptide sequence prediction from Lys-C digestion. (A) Expasy prediction of sequence
and mass (Da) of peptides resulting from digestion of recombinant SARS-CoV-2 N protein with Lys-C
protease. Highlighted in yellow is the largest peptide from the Lys-C digestion, containing 64 amino acids
and a peptide mass of 6544.070 Da. (B) Expasy prediction of sequence and mass (Da) of peptides resulting
from digestion of lambda protein with Lys-C. Highlighted in yellow is the peptide with mass 7694.657 Da.

3.3 Identification of phosphorylated sites on recombinant SARS-CoV-2 N protein
via ESI-MS and bottom-up analysis
In this study a recombinant SARS-CoV-2 N protein was expressed in eukaryotic
cells, which allows for the possibility for it to be phosphorylated by endogenous
eukaryotic kinases. Phosphorylation is a major posttranslational modification (PTM)
where a phosphoryl group is added to a serine, threonine and /or tyrosine. In this reaction,
the hydroxyl group from these residues is deprotonated, in basic conditions, which allows
the negatively charged oxygen to act as a nucleophile and attack the electrophilic
phosphorus atom and covalently add a phosphate group to the amino acid.
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Qualitative and quantitative analysis of phosphorylation can be done using a
bottom-up approach in which the protein is enzymatically digested into peptides followed
by electrospray ionization tandem mass spectrometry (ESI-MS/MS). Three different
procedures were used to proteolytically digest the purified recombinant N protein. In the
first procedure, the samples were digested with trypsin only and in the second and third
procedures the samples were digested with different amounts of Lys-C and trypsin
combinations, according to Table 1. Trypsin cuts proteins after both lysine and arginine,
while Lys-C only cuts after lysine. The SR domain is rich in arginine, making it unlikely
that we could detect phosphorylation sites within this domain using only trypsin, since
the peptides generated would be too small to be detected or for phosphorylation sites to
be confidently assigned within them. In procedures 1 and 2, high-energy C-trap
dissociation (HCD) was used to further fragment the peptides in an Orbitrap analyzer,
which gives b ions from the amino terminus and y ions from the carboxylic terminus. In
procedure 3, the peptides were fragmented using electron transfer dissociation (ETD),
generating multiply charged c and z ions mostly. ESI-MS/MS is helpful for localizing
phosphorylation sites since the generation of those ions from HCD and ETD
fragmentation can reveal the modified residues. The identification of mass-to-charge
ratios (m/z) from those ions allows the determination of the peptide sequence along with,
in many cases, the specific site of PTM occurrence. The fragmentation spectra of the
phosphorylated peptides identified in this study are shown in Figure 7 with their
respective sequences.
ETD fragmentation allows for more highly charged peptides and longer amino
acid sequences to be detected compared to HCD fragmentation, which can be
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advantageous for identifying phosphorylation sites. ETD has the additional benefit of
relatively unbiased peptide backbone fragmentation, compared to HCD. These features
have the potential to overcome some of the challenges to analyzing SR-rich domains
[43].
In this study, phosphorylation of S176 was identified using HCD fragmentation
from a sample digested with Lys-C and a low amount of trypsin, conditions which would
be expected to result in of complete digestion at lysine residues but only partial digestion
at arginine residues. Phosphorylation of S176 was also identified using ETD
fragmentation along with phosphorylated S180 in a peptide digested with Lys-C and
higher amount of trypsin (
Figure 8). The two digestion conditions generated the same peptide sequence,
however the peptide from HCD was found with a +2 charge and one phosphorylation site
the peptide from ETD was found with a +3 charge and 2 phosphorylation sites. In Figure
7A the fragmentation spectrum was rich in y and b ions and accurately localized the
phosphorylation site [44][45].
MaxQuant was used to analyze the raw ESI-MS/MS data files. Analysis of our
recombinant SARS-CoV-2 N protein expressed in insect cells revealed 12
phosphorylation sites including S2, S21, T24, T135, located in/near the RNA binding
region, S176, S180, S190, S193, S194, T198, located within the SR-rich region, T265,
and T329 located at the CTD domain where oligomerization occurs (Figure 9, Figure 10).
The 6 phosphorylation sites from the SR-rich domain as well as the first 3
phosphorylation sites from the N terminus were found in previous studies of cell lines
infected with actual SARS-CoV-2 virus, in which phosphopeptides were enriched using
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affinity techniques [46][47][48]. Collectively these studies found a total of 37
phosphorylation sites in SARS-CoV-2 N protein from the virus, 16 of them within the
SR-rich domain. Since the SR-rich domain contains 16 serines and threonines total, all
the possible phosphorylation sites were found to be in fact modified, according to those
studies although they couldn’t estimate occupancy. However, our MALDI data provides
occupancy of about 13 phosphorylation sites on average. Our research detected 3 novel
phosphorylation sites, T135, T265 and T329 located at the NTD and the CTD domains
(Figure 7). These experiments' inability to identify the three unique phosphorylation sites
might be attributed to differences in the technical approaches, or alternatively, the three
novel sites could be phosphorylated in the recombinant SARS-CoV-2 from insect cells
but not in the genuine virus.
Protein coverages, defined as the percentage of the amino acid residues identified
by ESI-MS/MS analysis, were 68.3%, 75.8%, and 60.7% from procedure 1, 2 and 3
respectively. These numbers reflect a successful protein analysis with high coverage
since total amino acid coverage is seldom accomplished with ESI-MS, unless different
combinations of proteases are used. This is because the digested protein may generate too
large or too small peptides that are not detectable within the mass range from the
instrument which cause the highly hydrophilic peptides to pass through the reverse phase
column and the highly hydrophobic peptides not to be eluted from the. In SARS-CoV-2
N protein, the SR-rich region also can influence a lower protein coverage because this
domain has a long 31 amino acid sequence with mass of 3129.1 Da and it is highly
phosphorylated with a dense negatively charge region. Protein digestion of SR-rich
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region is challenging as in the absence of missed cleavages extremely small peptides
from trypsin digestion occur which are not detectable or assignable in ESI-MS.
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Figure 7: ESI-MS/MS spectra showing the phosphorylation amino acid along with their peptide
sequence. (A) S2 (B) S190, S193, S194, T198 (C) S21 (D) T24 (E) T135 (F) T265 (G) T329.
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Figure 8: Comparison of HCD and ETD fragmentation of phosphopeptides from SARS-CoV-2 N protein
SR-rich domain. HCD fragmentation identified a phosphoserine at 176 while ETD fragmentation
identified two phosphorylation sites (S176 and S180).

Figure 9: Phosphorylated sites and peptide sequences identified from each enzymatic digestion
procedure.
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Figure 10: Phosphorylation sites found in SARS-CoV-2 N protein within the protein domains and amino
acid sequence. (A) Phosphorylation sites of SARS-CoV-2 Nucleocapsid protein. Novel sites in red. (B)
Amino acid sequence of SARS-CoV-2 Nucleocapsid protein. Amino acids highlighted in yellow represent
the phosphorylated residues and the SR-rich region is boxed in black. (Created with BioRender.com).

3.4 Autoproteolysis occurrence on SARS-CoV-2 N protein
Throughout the progress of this experiment, a consistent decrease over time in the
amount of purified recombinant SARS-CoV-2 N protein was observed via SDS-PAGE.
The SDS-PAGE band representing the recombinant SARS-CoV-2 N protein became
smaller and faded. For the GFP-tagged version of nucleocapsid the SDS-PAGE band
representing the GFP-tag became thicker with a more intense color. Therefore, the
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protein’s concentration, estimated using web application, Image J, decreased over time.
This observation led us to conclude that the recombinant SARS-CoV-2 N protein is
easily degraded. For this reason, extra precautions were taken in handling the protein to
avoid further degradation. Some of these precautions included storing the protein in cold
temperatures, such as -80° C degrees, whenever possible, and minimizing unnecessary
freezing/thawing cycles in an attempt to maintain the protein’s integrity. However,
further examination of SDS-PAGE results indicated that the extra care did not completely
prevent protein degradation. One possibility is that the observed protein degradation may
be autoproteolytic.
A recent publication has also indicated that SARS-CoV-2 N protein may be
autoproteolytically degraded [49]. According to this publication, autoproteolysis led to
the formation of five proteoforms with potential functions associated with the SARSCoV-2 N protein domains they contain. In 2020, the authors of this study proposed that
the proteoforms containing the CTD domain of SARS-CoV-2 N protein locate antigenic
regions and the ability to form oligomers as a function of pH, aiding in antibody
neutralization. Moreover, the proteoforms containing the NTD domain along with SRrich domain binds to virus RNA promoting virus proliferation [49].
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CHAPTER 4: CONCLUSION AND FUTURE WORK
4.1 Conclusion
The MALDI mass difference between the N protein samples that were treated and
non-treated with CIP and lambda clearly represents phosphorylation occurrence on
recombinant SARS-CoV-2 N protein. The recombinant SARS-CoV-2 sample treated
with CIP revealed that the untreated sample was phosphorylated by 13 phosphoryl groups
and the recombinant SARS-CoV-2 sample partially treated with lambda revealed that the
intact sample was phosphorylated by at least 9 phosphoryl groups.

Correlation of

MALDI results along with SDS-PAGE gels stained with Coomassie blue revealed the
phosphatase reaction with lambda protein was successful however it didn’t remove all the
phosphorylation from the recombinant SARS-CoV-2 N protein. This study encounters
analytical challenges to find phosphorylation on peptides generated from Lys-C digestion
and analyzed by MALDI-TOF. The difficulty detecting phosphopeptides by MALDI
might be associated with the fact that the signal is suppressed by the low sensitivity of
MALDI for phosphorylated peptides, and also the low abundance of these peptides [41].
Twelve phosphorylation sites were detected using ESI-MS/MS, of 3 are novel
sites. The majority of those phosphorylated sites are located within the RNA binding
region and SR-rich region. According to previous studies, SR-rich domain is detected to
be fully phosphorylated on serine and threonine [46]. Phosphorylation on SR-rich domain
changes the shape and charge of the domain compared to unphosphorylated SR-rich
domain. We can hypothesize that phosphorylation of SR-rich domain modulates RNA
binding. SARS-CoV-2 N protein is predicted to be slightly positively charged and have a
relatively high isoelectric point (pI) ~ 10, due to higher number of basic amino acids over
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the number of acidic amino acids. The addition of negatively charged phosphate group
will cause a decrease in the pI making the N protein less positive. This will repel the
interaction with the negatively charged RNA from SARS-CoV-2. Thus, we hypothesized
that phosphorylation of SARS-CoV-2 N protein decreases the RNA binding. The
disentangled interaction between the protein and the RNA allows RNA to be free for
translation and duplication. By contrast, the unphosphorylated N protein will likely binds
strongly to RNA which might serve as a protection to the genetic material.
4.2 Future Work
Further work can be done to find more phosphorylation sites in SARS-CoV-2
nucleocapsid protein, especially within the SR domain, which is predicted to be highly
modified. Improvements in methods procedures can be done to maximize results. For
example, increasing washings steps, trying different columns such as Ni-NTA during
purification procedure can help optimize percent yield and increase protein % coverage
analysis by mass spectrometry.
Peptide maps of proteins separated by 2 dimensional gel electrophoresis followed
by an enzymatic and chemically (such as cyanogen bromide) degradation in-gel reaction
is an alternative for detecting the presence of modifications. The peptides fragments can
be extracted from the gel with compatible solution for accurate MALDI-MS
measurements analysis without fractionation [32]. Another powerful approach to
investigate posttranslational modification on protein is the combination of manipulated
wet chemistry degradation in conjunction with MALDI-MS measurements of the amino
acid using protein ladder sequencing technique [32].
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Additionally, a simple and rapid technique for protein phosphorylation analysis
can be done by measuring the protein isoelectric point using gel-based isoelectric
focusing. Phosphorylated protein will cause a shift from predicted unphosphorylated
protein as the addition of negatively charged phosphate group (PO4-3) will lower the
isoelectric point and therefore effect protein migration on the 2-dimentional gel [50].
Highly phosphorylated protein will cause a higher shift on its isoelectric point.
Another significant technique to find phosphorylation on proteins in combination
with mass spectrometry is phosphopeptides enrichment using strategies such as affinity
chromatography, chemical modification or immunoprecipitants, which will increase the
number of phosphopeptides isolated from samples. This technique can be advantageous
to overcome the low abundance of phosphorylated proteins and peptides and signal
suppression caused by the phosphorylation.
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